Merck Q2 revenue up 28% to $14.6B; non-GAAP EPS $1.87 vs $0.61; raises 2022 sales guidance

Merck & Co., Inc.

2022-Q2 EPS reported $3.25 revenue$30,494,000,000

KEYTRUDA sales rose 26% to $5.3B; GARDASIL/GARDASIL 9 up 36% to $1.7B, driven by China demand.
LAGEVRIO contributed $1.2B in Q2 sales; full-year outlook maintained at $5.0-$5.5B.
GAAP EPS $1.55 vs $0.48; non-GAAP EPS $1.87 vs $0.61, reflecting strong operational performance.
Company raised and narrowed 2022 full-year sales guidance to $57.5-$58.5B (18-20% growth).
Non-GAAP EPS guidance narrowed to $7.25-$7.35; includes ~$0.09 impact from Orion upfront payment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.